Literature DB >> 30503374

The NMDA receptor intracellular C-terminal domains reciprocally interact with allosteric modulators.

Kiran Sapkota1, Kim Dore2, Kang Tang1, Mark Irvine3, Guangyu Fang3, Erica S Burnell4, Roberto Malinow2, David E Jane3, Daniel T Monaghan5.   

Abstract

N-methyl-d-aspartate receptors (NMDARs) have multiple prominent roles in CNS function but their excessive or insufficient activity contributes to neuropathological/psychiatric disorders. Consequently, a variety of positive and negative allosteric modulators (PAMs and NAMs, respectively) have recently been developed. Although these modulators bind to extracellular domains, in the present report we find that the NMDAR's intracellular C-terminal domains (CTDs) significantly influence PAM/NAM activity. GluN2 CTD deletion robustly affected NAM and PAM activity with both enhancing and inhibiting effects that were compound-specific and NMDAR subunit-specific. In three cases, individual PAMs became NAMs at specific GluN2-truncated receptors. In contrast to GluN2, GluN1 CTD removal only reduced PAM activity of UBP684 and CIQ, and did not affect NAM activity. Consistent with these findings, agents altering phosphorylation state or intracellular calcium levels displayed receptor-specific and compound-specific effects on PAM activity. It is possible that the GluN2's M4 domain transmits intracellular modulatory signals from the CTD to the M1/M4 channel gating machinery and that this site is a point of convergence in the direct or indirect actions of several PAMs/NAMs thus rendering them sensitive to CTD status. Thus, allosteric modulators are likely to have a marked and varied sensitivity to post-translational modifications, protein-protein associations, and intracellular ions. The interaction between PAM activity and NMDAR CTDs appears reciprocal. GluN1 CTD-deletion eliminated UBP684, but not pregnenolone sulfate (PS), PAM activity. And, in the absence of agonists, UBP684, but not PS, was able to promote movement of fluorescently-tagged GluN1-CTDs. Thus, it may be possible to pharmacologically target NMDAR metabotropic activity in the absence of channel activation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allosteric modulators; C-terminal domain; Desensitization; Fluorescence resonance energy transfer; N-methyl-d-aspartate; Phosphorylation

Mesh:

Substances:

Year:  2018        PMID: 30503374      PMCID: PMC7058367          DOI: 10.1016/j.bcp.2018.11.018

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  72 in total

1.  Deletion of the C-terminal domain of the NR2B subunit alters channel properties and synaptic targeting of N-methyl-D-aspartate receptors in nascent neocortical synapses.

Authors:  Ralf Mohrmann; Georg Köhr; Hanns Hatt; Rolf Sprengel; Kurt Gottmann
Journal:  J Neurosci Res       Date:  2002-05-01       Impact factor: 4.164

Review 2.  Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators.

Authors:  Daniel T Monaghan; Mark W Irvine; Blaise Mathias Costa; Guangyu Fang; David E Jane
Journal:  Neurochem Int       Date:  2012-01-17       Impact factor: 3.921

3.  Agonist binding to the NMDA receptor drives movement of its cytoplasmic domain without ion flow.

Authors:  Kim Dore; Jonathan Aow; Roberto Malinow
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-09       Impact factor: 11.205

4.  Subtype-dependence of N-methyl-D-aspartate receptor modulation by pregnenolone sulfate.

Authors:  M Horak; K Vlcek; H Chodounska; L Vyklicky
Journal:  Neuroscience       Date:  2005-10-28       Impact factor: 3.590

Review 5.  NMDA receptor subunits: function and pharmacology.

Authors:  Pierre Paoletti; Jacques Neyton
Journal:  Curr Opin Pharmacol       Date:  2006-11-07       Impact factor: 5.547

6.  C-terminal domains of N-methyl-D-aspartic acid receptor modulate unitary channel conductance and gating.

Authors:  Bruce A Maki; Teresa K Aman; Stacy A Amico-Ruvio; Cassandra L Kussius; Gabriela K Popescu
Journal:  J Biol Chem       Date:  2012-09-04       Impact factor: 5.157

7.  Intersubunit interactions at putative sites of ethanol action in the M3 and M4 domains of the NMDA receptor GluN1 and GluN2B subunits.

Authors:  Y Zhao; H Ren; R W Peoples
Journal:  Br J Pharmacol       Date:  2016-05-06       Impact factor: 8.739

Review 8.  Thinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.

Authors:  Joshua T Kantrowitz; Daniel C Javitt
Journal:  Clin Schizophr Relat Psychoses       Date:  2010-10

9.  Pharmacological characterization of recombinant NR1/NR2A NMDA receptors with truncated and deleted carboxy termini expressed in Xenopus laevis oocytes.

Authors:  C A Puddifoot; P E Chen; R Schoepfer; D J A Wyllie
Journal:  Br J Pharmacol       Date:  2009-01-16       Impact factor: 8.739

Review 10.  Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders.

Authors:  Giles E Hardingham; Hilmar Bading
Journal:  Nat Rev Neurosci       Date:  2010-09-15       Impact factor: 34.870

View more
  3 in total

Review 1.  Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels.

Authors:  Kasper B Hansen; Lonnie P Wollmuth; Derek Bowie; Hiro Furukawa; Frank S Menniti; Alexander I Sobolevsky; Geoffrey T Swanson; Sharon A Swanger; Ingo H Greger; Terunaga Nakagawa; Chris J McBain; Vasanthi Jayaraman; Chian-Ming Low; Mark L Dell'Acqua; Jeffrey S Diamond; Chad R Camp; Riley E Perszyk; Hongjie Yuan; Stephen F Traynelis
Journal:  Pharmacol Rev       Date:  2021-10       Impact factor: 18.923

Review 2.  NMDA Receptor C-Terminal Domain Signalling in Development, Maturity, and Disease.

Authors:  Kirsty Haddow; Peter C Kind; Giles E Hardingham
Journal:  Int J Mol Sci       Date:  2022-09-27       Impact factor: 6.208

Review 3.  Regulation of the NMDA receptor by its cytoplasmic domains: (How) is the tail wagging the dog?

Authors:  Yevheniia Ishchenko; Melissa G Carrizales; Anthony J Koleske
Journal:  Neuropharmacology       Date:  2021-06-20       Impact factor: 5.273

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.